Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR. Ramalingam SS, et al. Among authors: belani cp. J Thorac Oncol. 2010 Aug;5(8):1279-84. doi: 10.1097/JTO.0b013e3181e2fcb0. J Thorac Oncol. 2010. PMID: 20559150 Free PMC article. Clinical Trial.
Taxanes for advanced non-small cell lung cancer.
Ramalingam S, Belani CP. Ramalingam S, et al. Among authors: belani cp. Expert Opin Pharmacother. 2002 Dec;3(12):1693-709. doi: 10.1517/14656566.3.12.1693. Expert Opin Pharmacother. 2002. PMID: 12472367 Review.
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Fossella F, et al. Among authors: belani cp. J Clin Oncol. 2003 Aug 15;21(16):3016-24. doi: 10.1200/JCO.2003.12.046. Epub 2003 Jul 1. J Clin Oncol. 2003. PMID: 12837811 Clinical Trial.
Cyclooxygenase-2 inhibitors in lung cancer.
Ramalingam S, Belani CP. Ramalingam S, et al. Among authors: belani cp. Clin Lung Cancer. 2004 Jan;5(4):245-53. doi: 10.3816/CLC.2004.n.006. Clin Lung Cancer. 2004. PMID: 14967078 Review.
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ. Ramanathan RK, et al. Among authors: belani cp. Clin Cancer Res. 2005 May 1;11(9):3385-91. doi: 10.1158/1078-0432.CCR-04-2322. Clin Cancer Res. 2005. PMID: 15867239 Clinical Trial.
294 results